The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren’s Syndrome

Table 4

CD4+CD161+T cell subsets in the presence or absence of clinical or laboratory characteristics or ESSDAI ≥ 4 from pSS patients.

Characteristics	CD4+CD25+CD161+T/CD4+CD25+ T (%)		p value	CD4+CD25−CD161+T/CD4+CD25− T (%)		p value	CD4+CD161+T/CD4+ T (%)		p value
	Presence ()	Absence ()		Presence ()	Absence ()		Presence ()	Absence ()
Xerophthalmia (%)	12.70 ± 7.48 ()	15.19 ± 6.25 ()	0.377	17.47 ± 9.36 ()	19.79 ± 5.33 ()	0.500	17.39 ± 8.92 ()	19.34 ± 5.57 ()	0.553
Xerostomia (%)	12.83 ± 7.39 ()	15.93 ± 6.47 ()	0.419	17.58 ± 9.14 ()	20.65 ± 4.56 ()	0.511	17.47 ± 8.71 ()	20.23 ± 5.42 ()	0.537
Parotid gland enlargement (%)	10.53 ± 4.73 ()	13.33 ± 7.54 ()	0.380	14.27 ± 6.49 ()	18.20 ± 9.11 ()	0.311	13.70 ± 6.51 ()	18.11 ± 8.66 ()	0.233
Swollen and/or tender joints (%)	13.47 ± 9.34 ()	12.91 ± 6.68 ()	0.804	17.73 ± 7.97 ()	17.81 ± 9.28 ()	0.977	17.67 ± 7.82 ()	17.65 ± 8.82 ()	0.994
Interstitial lung diseases (%)	11.13 ± 5.83 ()	13.98 ± 7.85 ()	0.166	15.12 ± 8.33 ()	19.09 ± 9.00 ()	0.111	14.85 ± 8.33 ()	19.03 ± 8.38 ()	0.080
Leucopenia (%)	13.34 ± 7.10 ()	12.28 ± 6.38 ()	0.608	19.88 ± 12.45 ()	17.30 ± 7.64 ()	0.365	19.73 ± 11.49 ()	17.14 ± 7.43 ()	0.338
Anaemia (%)	11.19 ± 5.76 ()	13.18 ± 6.82 ()	0.303	20.95 ± 10.78 ()	16.60 ± 7.96 ()	0.102	20.12 ± 10.17 ()	16.74 ± 7.73 ()	0.183
Thrombocytopenia (%)	14.89 ± 6.01 ()	11.57 ± 6.55 ()	0.087	22.43 ± 11.37 ()	16.09 ± 7.30 ()	0.018	22.21 ± 10.69 ()	15.95 ± 6.95 ()	0.013
ANA(+) (%)	13.67 ± 7.56 ()	9.10 ± 3.93 ()	0.101	18.64 ± 9.22 ()	12.48 ± 3.86 ()	0.069	18.56 ± 8.71 ()	12.03 ± 4.33 ()	0.043
Anti-SSA(+) (%)	12.37 ± 6.61 ()	15.39 ± 9.30 ()	0.193	18.39 ± 9.71 ()	15.72 ± 5.05 ()	0.347	18.21 ± 9.18 ()	15.75 ± 5.57 ()	0.365
Anti-SSB(+) (%)	11.97 ± 5.96 ()	13.57 ± 7.92 ()	0.440	19.15 ± 11.02 ()	17.13 ± 7.76 ()	0.421	18.84 ± 10.40 ()	17.08 ± 7.52 ()	0.465
Anti-α-Fodrin(+) (%)	17.70 ± 6.79 ()	12.88 ± 7.34 ()	0.365	16.75 ± 8.13 ()	17.83 ± 9.00 ()	0.868	17.50 ± 8.34 ()	17.66 ± 8.60 ()	0.979
RF(+) (%)	13.23 ± 7.09 ()	12.83 ± 7.71 ()	0.838	19.78 ± 10.39 ()	15.50 ± 6.28 ()	0.060	19.50 ± 9.78 ()	15.54 ± 6.34 ()	0.077
Decreased C3 (%)	14.22 ± 6.89 ()	12.60 ± 7.51 ()	0.455	20.13 ± 12.43 ()	16.90 ± 7.14 ()	0.339	19.93 ± 11.69 ()	16.79 ± 6.94 ()	0.327
Decreased C4 (%)	15.21 ± 6.47 ()	12.36 ± 7.51 ()	0.207	19.45 ± 9.79 ()	17.26 ± 8.67 ()	0.428	19.19 ± 9.20 ()	17.17 ± 8.34 ()	0.444
Increased ESR (%)	12.73 ± 6.86 ()	13.78 ± 8.04 ()	0.600	20.83 ± 9.66 ()	14.74 ± 6.96 ()	0.010	20.53 ± 9.35 ()	14.86 ± 6.48 ()	0.012
Increased CRP (%)	11.36 ± 2.57 ()	13.20 ± 7.61 ()	0.595	19.82 ± 10.03 ()	17.60 ± 8.88 ()	0.599	18.60 ± 7.83 ()	17.57 ± 8.65 ()	0.798
Increased IgA (%)	11.51 ± 7.51 ()	13.58 ± 7.27 ()	0.350	21.09 ± 12.83 ()	16.64 ± 6.91 ()	0.217	20.65 ± 12.25 ()	16.61 ± 6.65 ()	0.241
Increased IgG (%)	13.67 ± 7.42 ()	12.46 ± 7.31 ()	0.535	19.61 ± 10.38 ()	16.09 ± 7.05 ()	0.135	19.31 ± 9.95 ()	16.11 ± 6.74 ()	0.154
Increased IgM (%)	10.60 ± 4.08 ()	13.27 ± 7.54 ()	0.440	21.78 ± 15.10 ()	17.41 ± 8.24 ()	0.299	20.10 ± 14.15 ()	17.43 ± 7.97 ()	0.507
Increased γ-globulin (%)	13.21 ± 6.96 ()	12.74 ± 8.14 ()	0.818	19.54 ± 10.00 ()	14.47 ± 5.07 ()	0.013	19.20 ± 9.49 ()	14.73 ± 5.36 ()	0.026
ESSDAI ≥ 4	13.13 ± 6.51 ()	12.94 ± 8.28 ()	0.922	20.11 ± 10.37 ()	15.13 ± 6.02 ()	0.032	19.71 ± 9.77 ()	15.30 ± 6.18 ()	0.049

Data were presented as mean ± SD. pSS: primary Sjögren’s syndrome; ANA: antinuclear antibodies; Anti-SSA: anti-Ro/SSA antibody; Anti-SSB: anti-La/SSB antibody; RF: rheumatoid factor; C3: complement component C3; C4: complement component C4; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M (IgM); ESSDAI: the EULAR-SS Disease Activity Index. The values in bold represent ones with statistical significance.